News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Offers to Give National Cancer Institute Rebate If Pfizer Inc. (PFE) Cancer Drug Better in Head to Head Clinical Trial


12/29/2010 6:47:29 AM

LONDON, Dec 24 (Reuters) - Britain's state-run health service will get a partial rebate from GlaxoSmithKline (GSK.L) if the company's new kidney cancer drug Votrient does not match up to a rival medicine in a head-to-head clinical trial. The unusual deal, the first of its kind, hints at the type of complex arrangements that could become commonplace as Britain moves to a system of value-based drug pricing from the end of 2013.

Read at Reuters
Read at Financial Times
Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES